Anna Choromańska

Dr. Anna Choromańska

Department of Molecular and Cellular Biology, Wroclaw Medical University, 50-367 Wrocław, Poland
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ACAnna Choromańska
Anna Choromańska
Julita KulbackaJulita Kulbacka
Julita Kulbacka
NRNina Rembialkowska
Nina Rembialkowska
JPJustyna Pilat
Justyna Pilat
RORemigiusz Oledzki
Remigiusz Oledzki
JSJolanta Saczko
Jolanta Saczko

23 June 2017
Verified
Book Chapter
Closed access
PDF file
Julita KulbackaJulita Kulbacka
Julita Kulbacka
ACAnna Choromańska
Anna Choromańska
JRJoanna Rossowska
Joanna Rossowska
JWJoanna Wezgowiec
Joanna Wezgowiec
JSJolanta Saczko
Jolanta Saczko
Marie-Pierre RolsMarie-Pierre Rols
Marie-Pierre Rols

Verified
Journal Article
Open access
PDF file
MNMonika Nowak
Monika Nowak
JGJulia Górczyńska
Julia Górczyńska
KKKatarzyna Kołodzińska
Katarzyna Kołodzińska
JRJakub Rubin
Jakub Rubin
ACAnna Choromańska
Anna Choromańska
Extracellular vesicles (EVs) are lipid bilayer-delimited particles. According to their size and synthesis pathway, EVs can be classified into exosomes, ectosomes (microvesicles), and apoptotic bodies. Extracellular vesicles are of great interest to the scientific community due to their role in cell-to-cell communication and their drug-carrying abilities. The study aims to show opportunities for the application of EVs as drug transporters by considering techniques applicable for loading EVs, current limitations, and the uniqueness of this idea compared to other drug transporters. In addition, EVs have therapeutic potential in anticancer therapy (especially in glioblastoma, pancreatic cancer, and breast cancer).

Verified
Journal Article
Open access
PDF file
PTPaulina Tomecka
Paulina Tomecka
Dominika KunachowiczDominika Kunachowicz
Dominika Kunachowicz
JGJulia Górczyńska
Julia Górczyńska
MGMichał Gebuza
Michał Gebuza
JKJacek Kuźnicki
Jacek Kuźnicki
ACAnna Choromańska
Anna Choromańska
Epithelial-mesenchymal transition (EMT) is a process in which an epithelial cell undergoes multiple modifications, acquiring both morphological and functional characteristics of a mesenchymal cell. This dynamic process is initiated by various inducing signals that activate numerous signaling pathways, leading to the stimulation of transcription factors. EMT plays a significant role in cancer progression, such as metastasis and tumor heterogeneity, as well as in drug resistance. In this article, we studied molecular mechanisms, epigenetic regulation, and cellular plasticity of EMT, as well as microenvironmental factors influencing this process. We included both in vivo and in vitro models in EMT investigation and clinical implications of EMT, such as the use of EMT in curing oncological patients and targeting its use in therapies. Additionally, this review concludes with future directions and challenges in the wide field of EMT.

29 July 2017 in Pathology and Oncology Research
Verified
Journal Article
Open access
PDF file
ACAnna Choromańska
Anna Choromańska
Julita KulbackaJulita Kulbacka
Julita Kulbacka
Joanna HarasymJoanna Harasym
Joanna Harasym
RORemigiusz Oledzki
Remigiusz Oledzki
ASAnna Szewczyk
Anna Szewczyk
JSJolanta Saczko
Jolanta Saczko
Beta-glucans are widely used in treatment, cosmetics, and the food industry. Glucans play a significant role in activation of the immune and antioxidant system and inhibiting tumor proliferation. In the current study the antitumor activities of new high and low molecular weight beta-glucan derived from oats were investigated in two human lung cancer cell line (A549, H69AR) and normal keratinocytes (HaCaT). The effect of high and low molecular weight beta-glucan from oat was evaluated by cellular viability assessment, lipid peroxidation and manganese superoxide dismutase evaluation and cytoskeleton visualisation. Additionally the level of red blood cells hemolysis was performed. Our results indicate strong anti-tumor properties of new beta-glucan from oat and at the same time no toxicity for normal cells.

15 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
USUrszula Szwedowicz
Urszula Szwedowicz
Zofia ŁapińskaZofia Łapińska
Zofia Łapińska
AGAgnieszka Gajewska-Naryniecka
Agnieszka Gajewska-Naryniecka
ACAnna Choromańska
Anna Choromańska
Until thirty years ago, it was believed that extracellular vesicles (EVs) were used to remove unnecessary compounds from the cell. Today, we know about their enormous potential in diagnosing and treating various diseases. EVs are essential mediators of intercellular communication, enabling the functional transfer of bioactive molecules from one cell to another. Compared to laboratory-created drug nanocarriers, they are stable in physiological conditions. Furthermore, they are less immunogenic and cytotoxic compared to polymerized vectors. Finally, EVs can transfer cargo to particular cells due to their membrane proteins and lipids, which can implement them to specific receptors in the target cells. Recently, new strategies to produce ad hoc exosomes have been devised. Cells delivering exosomes have been genetically engineered to overexpress particular macromolecules, or transformed to release exosomes with appropriate targeting molecules. In this way, we can say tailor-made therapeutic EVs are created. Nevertheless, there are significant difficulties to solve during the application of EVs as drug-delivery agents in the clinic. This review explores the diversity of EVs and the potential therapeutic options for exosomes as natural drug-delivery vehicles in oncology, neurology, and dermatology. It also reflects future challenges in clinical translation.